Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003178 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00003178 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 120 participants.
The verdict
NCT00003178, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of idarubicin and cladribine in treating children who have recurrent acute myeloid leukemia.
Interventions
- BIOLOGICAL filgrastim
- DRUG idarubicin
- DRUG cladribine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1998-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003178
The ClinicalTrials.gov registry entry for NCT00003178 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which filgrastim is the first listed.
NCT00003178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003178 about?
NCT00003178 is a clinical study titled "Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of idarubicin and cladribine in treating children who have recurrent a...
What is the current status of trial NCT00003178?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 1998-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00003178?
The interventions under investigation include: filgrastim (BIOLOGICAL), idarubicin (DRUG), cladribine (DRUG).
Who is sponsoring clinical trial NCT00003178?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.